Piper Sandler raised the firm’s price target on Collegium Pharmaceutical (COLL) to $37 from $36 owing to slightly higher estimates for the legacy pain management business, while keeping an Overweight rating on the shares. The firm notes Collegium reported Q1 adjusted diluted EPS of $1.49 on revenue of $177.8M, compared to consensus of $1.43 and $172.0M, respectively. Guidance for 2025 was unchanged.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Strong Buy Rating for Collegium Pharmaceutical Driven by Robust 2025 Performance and Growth Potential
- Collegium Pharmaceutical Reports Strong Q1 2025 Growth
- Collegium Pharmaceutical Reports 23% Revenue Increase
- Collegium Pharmaceutical reports Q1 adjusted EPS $1.49, consensus $1.45
- Collegium Pharmaceutical backs FY25 revenue view $735M-$750M, consensus $742.47M